19 Paul Tudor Jones II ITT Trades
The first ITT trade was made in Q4 2016. Since then Paul Tudor Jones II bought shares nine more times and sold shares on nine occasions. The investor completely sold their stake between Q4 2023 and Q3 2024.
Avg closing price
Price range
Sold -6.36 Thousand shares
Q3 2024
Avg closing price
$136.05
Price range
$125.05
-
$150.55
Sold 86.7% shares (-41.5 Thousand shares)
Q2 2024
Avg closing price
$131.31
Price range
$124.49
-
$139.66
Sold 46.5% shares (-41.6 Thousand shares)
Q1 2024
Avg closing price
$124.02
Price range
$113.72
-
$137.08
Sold 17.4% shares (-18.9 Thousand shares)
Q4 2023
Avg closing price
$105.13
Price range
$92.13
-
$120.52
Increased shares by 26.6% (+22.8 Thousand shares)
Q3 2023
Avg closing price
$98.13
Price range
$91.94
-
$103.40
Increased shares by 13.6% (+10.3 Thousand shares)
Q2 2023
Avg closing price
$83.98
Price range
$76.16
-
$93.21
New holding (+75.3 Thousand shares)
Q1 2023
Avg closing price
$87.90
Price range
$79.21
-
$94.53
Sold -48.5 Thousand shares
Q4 2020
Avg closing price
$69.88
Price range
$58.54
-
$78.61
Increased shares by 1182.0% (+44.8 Thousand shares)
Q3 2020
Avg closing price
$60.61
Price range
$55.74
-
$64.56
New holding (+3.79 Thousand shares)
Q2 2020
Avg closing price
$52.99
Price range
$43.97
-
$64.89
Sold -3.93 Thousand shares
Q1 2020
Avg closing price
$62.03
Price range
$37.99
-
$75.55
New holding (+3.93 Thousand shares)
Q4 2019
Avg closing price
$66.45
Price range
$55.20
-
$74.16
Sold -9.26 Thousand shares
Q1 2019
Avg closing price
$54.58
Price range
$47.07
-
$59.00
Increased shares by 12.3% (+1.01 Thousand shares)
Q4 2018
Avg closing price
$52.83
Price range
$45.29
-
$61.10
New holding (+8.25 Thousand shares)
Q3 2018
Avg closing price
$57.73
Price range
$51.70
-
$62.14
Sold -12.3 Thousand shares
Q2 2018
Avg closing price
$52.17
Price range
$47.46
-
$55.20
New holding (+12.3 Thousand shares)
Q1 2018
Avg closing price
$52.80
Price range
$47.96
-
$57.43
Sold -10.5 Thousand shares
Q1 2017
Avg closing price
$41.12
Price range
$39.11
-
$43.36
New holding (+10.5 Thousand shares)
Q4 2016
Avg closing price
$37.68
Price range
$33.26
-
$42.73
News about ITT Inc and Paul Tudor Jones II
AstraZeneca’s Beyfortus recommended for approval in the EU by CHMP
AstraZeneca plc (LON:AZN) and Sanofi''s Beyfortus (nirsevimab) has been recommended for marketing authorisation in the European Union (EU) for the prevention...
US FDA grants Priority Review to Roches Tecentriq as adjuvant treatment for certain people with early non-small cell lung cancer
Basel, 3 August 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has accepted the companys supplement...